Deutsche Bank
CCCC icon

Deutsche Bank’s C4 Therapeutics CCCC Stock Holding History

Deutsche Bank’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-46,225
Closed -$74K – 3626
2025
Q1 		$74K Buy
+46,225
New +$138K ﹤0.01% 3291
2024
Q4 		– Sell
-39,180
Closed -$223K – 3622
2024
Q3 		$223K Buy
39,180
+9,332
+31% +$56.2K ﹤0.01% 2882
2024
Q2 		$138K Buy
+29,848
New +$178K ﹤0.01% 3002
2023
Q2 		– Sell
-25,932
Closed -$81.4K – 3827
2023
Q1 		$81.4K Buy
25,932
+8,162
+46% +$48.1K ﹤0.01% 3412
2022
Q4 		$105K Buy
17,770
+281
+2% +$2.33K ﹤0.01% 3308
2022
Q3 		$153K Sell
17,489
-939
-5% -$9.75K ﹤0.01% 3099
2022
Q2 		$139K Sell
18,428
-8,562
-32% -$75.3K ﹤0.01% 3356
2022
Q1 		$654K Sell
26,990
-29,050
-52% -$705K ﹤0.01% 2593
2021
Q4 		$1.8M Buy
56,040
+31,854
+132% +$1.26M ﹤0.01% 2064
2021
Q3 		$1.08M Buy
24,186
+2,327
+11% +$99.7K ﹤0.01% 2561
2021
Q2 		$828K Buy
21,859
+14,645
+203% +$525K ﹤0.01% 2893
2021
Q1 		$267K Sell
7,214
-648
-8% -$25.8K ﹤0.01% 3473
2020
Q4 		$260K Buy
+7,862
New +$228K ﹤0.01% 3323

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank's CCCC Position: Q2 2025 in Review

Deutsche Bank sold out of C4 Therapeutics (CCCC) in Q2 2025, closing a stake of 46,225 shares — an estimated $74K sold.

Deutsche Bank first reported a position in CCCC in Q4 2020 and held it in 13 quarters. The position peaked at $1.8M in Q4 2021. 102 funds tracked by Wall St. Rank hold CCCC as of Q2 2025.

  • Deutsche Bank reported no remaining C4 Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Deutsche Bank sold 46,225 C4 Therapeutics shares in Q2 2025, an estimated $74K.
  • Deutsche Bank first reported a position in C4 Therapeutics in Q4 2020 and held it in 13 quarters.
  • Deutsche Bank's C4 Therapeutics position peaked at $1.8M in Q4 2021.
  • 102 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2025.

Based on Deutsche Bank's 13F filing for Q2 2025, filed 12 Aug 2025.